Citation Tools

Download PDFPDF

529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors
Free

Download to a citation manager

Cite this article as:
Cutsem EV, Prenen H, Delafontaine B, et al
529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors